Weight Watchers Expands GLP-1 Platform With Wegovy Pill Access

Weight Watchers announced access to Novo Nordisk’s newly FDA-approved oral formulation of Wegovy through its integrated GLP-1 platform, expanding treatment options beyond injectable therapies.

• Company is a NovoCare Recognized Care Provider for delivering FDA-approved GLP-1 medications
• Med+ members can access the oral formulation starting at $149 per month
• Engaged Med+ members lost 29.1% more weight than those without behavioral support

To view the source of this information, click here

To contact the reporter on this story:
Georgi Azar in New York at gazar4@bloomberg.net

To contact the editors responsible for this story:
Ilya Banares at ibanares@bloomberg.net

Georgi Azar

© 2026 Bloomberg ...